Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 2054 results found since Jan 2013.

Retroperitoneal fibrosis: A literature review.
CONCLUSION: Unfortunately, despite a recent surge in the number of publications on this topic, a few progress has been made in our understanding of the classification, pathophysiology, and, most importantly, the most appropriate treatment for this disease. PMID: 31950925 [PubMed - in process]
Source: Archivos Espanoles de Urologia - January 18, 2020 Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Stimulation of Leydig and Sertoli cellular secretory function by anti-oestrogens: Tamoxifen.
In this study, we performed a literature search of the OVID medline database and identified 37 studies describing the effects of tamoxifen which we then reviewed. Evidence suggests Tamoxifen effectively increases androgen levels and sperm concentrations in males with idiopathic oligozoospermia. Evidence for increased motility and pregnancy rates in these patients is less conclusive. Further randomised control trials are needed to elucidate the safety of Tamoxifen combination therapies and their efficacy in improving pregnancy rates. PMID: 32053070 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 11, 2020 Category: Drugs & Pharmacology Authors: Dimakopoulou A, Foran D, Jayasena CN, Minhas S Tags: Curr Pharm Des Source Type: research

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
CONCLUSIONS: This review found evidence that supports adding OFS for premenopausal women with early, hormone receptor-positive breast cancers. The benefit of OFS persisted when compared to observation, and when added to endocrine therapy (tamoxifen) or chemotherapy and endocrine therapy (tamoxifen). The decision to use OFS may depend on the overall risk assessment based on tumour and patient characteristics, and may follow consideration of all side effects that occur with the addition of OFS. PMID: 32141074 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - March 5, 2020 Category: General Medicine Authors: Bui KT, Willson ML, Goel S, Beith J, Goodwin A Tags: Cochrane Database Syst Rev Source Type: research

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
ConclusionsPharmacogenomics could play important roles in mediating the advancement of tamoxifen-based adjuvant therapies. Research efforts should be directed towards the exploration of further SNPs of CYP2D6 that affect tamoxifen metabolism, as well as epigenetic changes in CYP2D6, enabling the design of precision medicine and confirming clinical validity in the use of pharmacogenomics for tamoxifen.
Source: Journal of Cancer Research and Clinical Oncology - April 7, 2020 Category: Cancer & Oncology Source Type: research

Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer.
Abstract In search for new and effective treatments of breast and prostate cancer, a series of hybrid compounds based on tamoxifen, estrogens and artemisinin were successfully synthesized and analyzed towards their in vitro activities against human prostate (PC-3) and breast cancer (MCF-7) cell lines. Most of the hybrid compounds exhibit a strong anti-cancer activity against both cancer cell lines e.g., EC 50 (PC-3) down to 1.07 µM and EC 50 (MCF-7) down to 2.08 µM, thus showing higher activities than their parent compounds 4-hydroxytamoxifen (Afimoxifene, 7 ) (EC 50 (PC-3) = 75.1 µM and EC 50 (MCF-7) = 19.3 µ...
Source: ChemMedChem - May 5, 2020 Category: Chemistry Authors: Fröhlich T, Mai C, Bogautdinov R, Morozkina SN, Shavva AG, Friedrich O, Gilbert D, Tsogoeva SB Tags: ChemMedChem Source Type: research

Tamoxifen for hepatocellular carcinoma.
Abstract The review is withdrawn as it has not been updated since its last search for trials in 2004. PMID: 32748416 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - August 2, 2020 Category: General Medicine Authors: Nowak AK, Findlay M, Culjak G, Stockler MR Tags: Cochrane Database Syst Rev Source Type: research

Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations
Background Patients with hormone receptor-positive breast tumors receive hormonal therapy with either selective estrogen receptor modulators (SERMs) (eg, tamoxifen) or aromatase inhibitors (AIs) (eg, anastrozole) for 5 to 10 years. Patients are using these therapies frequently during breast reconstruction. Literature investigating the effects of hormonal modulators on breast reconstruction outcomes demonstrates conflicting results. We sought to perform a systematic evaluation to assess the effects of hormonal therapy on breast reconstruction outcomes and to guide perioperative management of antiestrogen therapies. Metho...
Source: Annals of Plastic Surgery - September 15, 2020 Category: Cosmetic Surgery Tags: Review Paper Source Type: research

Therapeutic drug monitoring of oral targeted antineoplastic drugs
ConclusionSub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.
Source: European Journal of Clinical Pharmacology - November 9, 2020 Category: Drugs & Pharmacology Source Type: research

Synthesis and Clinical Development of Palbociclib: An overview.
Abstract Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer. The past few years have seen a substantial increase in breast cancer awareness campaigns and active research in fields of diagnosis and targeted therapy. These factors have led to a better mechanistic understanding of the disease, detection at earlier stages and more personalized approach to treatment, ultimately causing a crucial increase in the survival rates after detection. However, with the advances in treatment, cases of patients developing primary resistance and acquired resistance are incre...
Source: Medicinal Chemistry - December 4, 2020 Category: Chemistry Authors: Konar D, Maru S, Kar S, Kumar K Tags: Med Chem Source Type: research

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
CONCLUSIONS: The LNG-IUS probably slightly reduces the incidence of benign endometrial polyps and endometrial hyperplasia in women with breast cancer taking tamoxifen. At 12 and 24 months of follow-up, the LNG-IUS probably increases abnormal vaginal bleeding or spotting among women in the treatment group compared to those in the control. Data were lacking on whether the LNG-IUS prevents endometrial cancer in these women. There is no clear evidence from the available RCTs that the LNG-IUS affects the risk of breast cancer recurrence or breast cancer-related deaths. Larger studies are necessary to assess the effects of the L...
Source: Cochrane Database of Systematic Reviews - December 21, 2020 Category: General Medicine Authors: Romero SA, Young K, Hickey M, Su HI Tags: Cochrane Database Syst Rev Source Type: research

Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer
AbstractPurposeMost of the existing literature reports no association or a slight negative association between coffee consumption and the risk of developing breast cancer. However, the level of risk differs when considering various subgroups, such as menopausal status, hormonal status of the tumor or genetic mutations. The present review based on a literature search sets the point on the potential influence of a common daily drink, coffee, on the risk of developing breast cancer in the general population, in different subgroups of women and the consequences of drinking coffee after breast cancer has been diagnosed and trea...
Source: European Journal of Nutrition - January 13, 2021 Category: Nutrition Source Type: research

Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis
ConclusionsThe incidence of BRCA mutations in patients with endometrial carcinoma is about 0.035 according to present studies, the incidence of endometrial carcinoma in BRCA carriers is about 0.004. Tamoxifen use is a certain risk factor for subsequent endometrial carcinoma, while history of breast cancer or risk-reducing BSO is not associated with incidence of follow-up endometrial carcinoma. The necessity and rationality of prophylactic hysterectomy for BRCA carriers remained to be discussed.
Source: Archives of Gynecology and Obstetrics - April 30, 2021 Category: OBGYN Source Type: research

Triazine Derivative as Putative Candidate for the Reduction of Hormone-Positive Breast Tumor: In Silico, Pharmacological, and Toxicological Approach
Conclusion: All results indicated the anti–breast tumor activity of O-NPAT and presented its possibility of exploitation for beneficial effects in breast cancer treatment.
Source: Frontiers in Pharmacology - May 28, 2021 Category: Drugs & Pharmacology Source Type: research

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Discussion: Targeted treatment options for HR + BC have evolved. The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes.PMID:34064867 | DOI:10.3390/curroncol28030168
Source: Current Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Samitha Andrahennadi Amer Sami Mita Manna Mehrnoosh Pauls Shahid Ahmed Source Type: research